Overview Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indication: In combination with chemotherapy, with the therapy of adult people with locally recurrent unresectable or metastatic triple-adverse breast most cancers who have not gained prior chemotherapy for metastatic ailment and whose tumours Categorical programmed cell Loss of life-ligand 1 (mixed constructive rating ≥ https://eduardocilno.newbigblog.com/42175266/the-keytruda-cost-diaries